Corbus posts Phase 1a data for CRB-913: weight loss signal, no serious AEs; Phase 1b started

Corbus Pharmaceuticals Holdings, Inc.

Phase 1a SAD/MAD of oral CB1 inverse agonist CRB-913 (n=112) showed no serious AEs, no GI intolerability, no neuropsychiatric events except mild anxiety/irritability in obese cohort.
In obese MAD cohort (150 mg QD), all 9 CRB-913-treated participants lost weight; mean placebo-adjusted 2.9% loss at Day 14 (range 1.3-4.3%).
Initiated Phase 1b CANYON-1 (12-week, 240 obese non-diabetic participants, doses 20/40/60 mg); completion expected summer 2026.
PK profile supports once-daily dosing; no suicidality, depression, or insomnia reported across all study cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.